Inhibition of breast cancer growth with the combination of lapatinib and an ADAM protease inhibitor

被引：0
|
作者：
Witters, L. M.
Scherle, P. A.
Friedman, S. M.
Redman, J.
Fridman, J. S.
Caulder, E.
Lipton, A.
机构：
[1] Penn State Univ, Coll Med, Hershey, PA USA
[2] Incyte Corp, Wilmington, DE USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S82 / S82
页数：1
相关论文
共 50 条
  • [41] Inhibition of c-ABL Sensitizes Breast Cancer Cells to the Dual ErbB Receptor Tyrosine Kinase Inhibitor Lapatinib (GW572016)
    Lo, Yuan-Hung
    Ho, Po-Chun
    Zhao, Huajun
    Wang, Shao-Chun
    ANTICANCER RESEARCH, 2011, 31 (03) : 789 - 795
  • [42] Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine
    George Dranitsaris
    Mario E. Lacouture
    Breast Cancer Research and Treatment, 2014, 147 : 631 - 638
  • [43] cMET Inhibitor and the Inhibition of Growth of Breast Cancer Cells in Bone Marrow Matrix Environment.
    Ye, L.
    Mason, M. D.
    Bramble, P.
    Jiang, W. G.
    CANCER RESEARCH, 2011, 71
  • [44] Dynamic Model of Protease State and Inhibitor Trafficking to Predict Protease Activity in Breast Cancer Cells
    W. Andrew Shockey
    Christopher A. Kieslich
    Catera L. Wilder
    Valencia Watson
    Manu O. Platt
    Cellular and Molecular Bioengineering, 2019, 12 : 275 - 288
  • [45] Inhibition of γ-secretase in combination with Lapatinib induces tumor regression in vivo
    Pandya, Kinnari
    Meeke, Kathleen
    Rogowski, Allison
    Clementz, Anthony
    Osipo, Clodia
    CANCER RESEARCH, 2011, 71
  • [46] GlaxoSmithKline receives approval from the EMA for lapatinib in combination with trastuzumab for the treatment of metastatic breast cancer
    Wilkinson, Jonathan
    FUTURE ONCOLOGY, 2013, 9 (10) : 1421 - 1422
  • [47] Dynamic Model of Protease State and Inhibitor Trafficking to Predict Protease Activity in Breast Cancer Cells
    Shockey, W. Andrew
    Kieslich, Christopher A.
    Wilder, Catera L.
    Watson, Valencia
    Platt, Manu O.
    CELLULAR AND MOLECULAR BIOENGINEERING, 2019, 12 (04) : 275 - 288
  • [48] Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer
    Sardesai, Sagar D.
    Storniolo, Anna Maria
    WOMENS HEALTH, 2015, 11 (03) : 281 - 294
  • [49] Synergistic Effect of Lapatinib and the Class 1 HDAC Inhibitor SNDX-275 in Breast Cancer
    LaFortune, T. A.
    Ordentlich, P.
    Zhang, D.
    Hortobagyi, G. N.
    Cristofanilli, M.
    Ueno, N. T.
    CANCER RESEARCH, 2009, 69 (24) : 691S - 691S
  • [50] A phase I trial of pegylated liposomal anthracycline and lapatinib (L) combination in the treatment of metastatic breast cancer (MBC): First evaluation of an anthracycline and lapatinib combination in the treatment of MBC
    Cianfrocca, M. E.
    Rosen, S. T.
    von Roenn, J. H.
    Rademaker, A. W.
    Rubin, S. D.
    Friedman, R. A.
    Rozario, C. P.
    Gradishar, W. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345